Announcement • Apr 01
Northwest Biotherapeutics, Inc. announced delayed annual 10-K filing On 03/31/2026, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Nov 20
Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025 Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025. Location: gibson, dunn & crutcher llp, 1700 m st nw, washington, dc 20036, United States Announcement • Aug 28
Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million. Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million on August 27, 2025. The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Northwest's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable due from Northwest to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in Northwest’s public filings. The Net AP payable by Northwest will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties. As part of the acquisition, Northwest will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to Northwest (13.5 million shares and 5.5 million options). Certain intellectual property and other intangibles that Advent has acquired will also transfer to Northwest. At closing, Advent will become a wholly owned subsidiary of Northwest, and this is expected to enable Northwest’s operations to become fully integrated. The acquisition is also expected to enhance Northwest’s positioning for scale-up of operations, and yield important synergies and cost savings.
The transaction is expected to close as soon as certain legal conditions are fulfilled. Announcement • Aug 19
Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman Northwest Biotherapeutics, Inc. announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time. Announcement • Jul 02
Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million. Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 17,727,273
Price\Range: $0.22 Announcement • Jun 12
Northwest Biotherapeutics Announces Upcoming Presentation on Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments Northwest Biotherapeutics announced that Dr. Marnix Bosch, its Chief Technical Officer, will make a presentation on "Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses" at the upcoming Frontiers in Cancer Immunotherapy Conference of the New York Academy of Sciences. Dr. Bosch will address certain factors and combinations of factors that may lead to supercharged dendritic cells with enhanced anti-tumor effects. The presentation will take place on June 16, at 2:50 p.m. The slides will be posted on the company's website after the presentation. Announcement • Dec 27
Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million. Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 21,587,302
Price\Range: $0.255
Discount Per Security: $0.019125
Transaction Features: Registered Direct Offering Announcement • May 25
Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024 Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024. Location: offices of gibson, dunn & crutcher llp, 1050 connecticut avenue nw, washington, dc 20036, United States Announcement • Mar 22
Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors Northwest Biotherapeutics announced that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024. Mr. Sarma will initially complete the remainder of Mr. Jerry Jasinowski's term as an independent director, following Mr. Jasinowski's retirement due to health reasons as previously reported. Mr. Sarma will serve as the Chairman of the Audit Committee and member of the Compensation and Conflicts Committees. Mr. Sarma is a longtime shareholder of NWBio. In the joining the Board, he brings decades of experience as a business executive and as a venture capital investor. One of the companies he founded and built was American Megatrends Inc. (AMI), which became a major player in hardware, software and firmware components of PC-based systems. The company was known for developing the AMIBIOS firmware program for IBM-PC compatibility. The BIOS (Basic Input Output System) is the heart of PC-compatibility and all application programs access the BIOS in reading from or writing to peripheral units such as drives, keyboards, mouse. Mr. Sarma's interests in AMI were acquired, and thereafter he became a venture capital investor in the private equity markets. He was an owner for a number of years of the N.J. Devils team in the National Hockey League, and has invested in a diverse range of industries including medical and environmental companies. Mr. Sarma has been an investor in NWBio for more than a decade. Mr. Sarma received a Master's Degree in Industrial Engineering and Operations Research from Georgia Tech and a Bachelor's Degree in Mechanical Engineering from the University of Madras. Announcement • Mar 03
Northwest Biotherapeutics, Inc. announced delayed annual 10-K filing On 03/01/2024, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Dec 22
Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for Glioblastoma Northwest Biotherapeutics announced that a Marketing Authorization Application (MAA) was submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®?-L for glioblastoma brain cancer. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs. GBM is the most lethal and most common form of primary brain cancer. Despite well over 400 clinical trials of a wide range of treatment agents, patient survival in newly diagnosed GBM is only 15-17 months and has not meaningful improved in 20 years; survival in recurrent GBM is only 6-8 months and has not improved in 30 years. The Company's international Phase III trial demonstrated a statistically significant and clinically meaningful extension of median survival in both newly diagnosed and recurrent GBM in patients treated with DCVax-L compared with independently selected, matched, contemporaneous, pre-specified external controls. The trial also demonstrated more than doubling of the percentage of patients alive at 5 years in newly diagnosed GBM, and more than doubling of patients alive at 3 years after tumor recurrence in recurrent GBM patients, although the numbers of patients available for comparison at late time points was small, especially in the external control populations. One of the key factors making GBM so difficult to treat is that it is an extremely heterogeneous tumor. DCVax-Direct involves essentially the same mechanism of action as DCVax-L, except that the tumor target proteins are taken up by the dendritic cells in situ in the tumor following intra-tumoral injection, rather than from tumor lysate from a surgically resected tumor tissue sample. The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors. For the GBM MAA, the Company anticipates that the review process will be a period of intensive and extensive further work involving responding to questions and requests for further information by the regulatory authority as well as preparing for and undergoing detailed inspections of the contract research organizations (CROs) that managed the trial, the Sponsor, the Trial Master File, a number of individual trial sites selected by the regulatory from among the 94 sites that participated in the trial, the GMP facility and manufacturing information. Announcement • Sep 13
Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory Board Northwest Biotherapeutics announced that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine. The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing. 
